High-grade glioma is the most aggressive form of brain cancer. Despite improvements in surgical procedures, chemotherapy, and radiotherapy, this type of brain tumor is still notoriously hard to treat: less than 10 percent of patients survive beyond five years. Researchers have now shown that next-generation cell-based immunotherapy may offer new hope in the fight against brain cancer.